It has been confirmed that PI3K-Akt-mTOR plays a role in Gorham syndrome pathogenesis, which provides a theoretical basis for using sirolimus in the clinical treatment of Gorham syndrome. This evidence concerns the gene AKT1 and Gorham-Stout disease.